Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rare EGFR L747P mutation and bone metastases: a case report - Top-Institutions - MDSpire

Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rare EGFR L747P mutation and bone metastases: a case report

  • By

  • Weixin Su

  • Haiyan Deng

  • Zhi Yang

  • Anjian Gao

  • Bo Gao

  • May 5, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Guangdong Lung Cancer Institute
    Guangdong Lung Cancer Institute

    Guangzhou, Guangdong

    Key Differentiators

    • Oncology

  • #3

    Virginia Cancer Specialists Research Institute
    Virginia Cancer Specialists Research Institute

    Fairfax, VA

    Key Differentiators

    • Oncology

  • #4

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, Île-de-France

    Key Differentiators

    • Oncology

  • #5

    National Taiwan University College of Medicine
    National Taiwan University College of Medicine

    Taipei, Taiwan

    Key Differentiators

    • Oncology

Original Source(s)

Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rare EGFR L747P mutation and bone metastases: a case report

  • by Weixin Su, Haiyan Deng, Zhi Yang, Anjian Gao, Bo Gao

  • May 5, 2026

Related Content

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship